Phase 2 Multicenter Randomized Study of DS-1062a in Advanced or Metastatic NSCLC w/ Actionable Genomic Alterations and Previously Treated with Kinase Inhibitor Therapy and Platinum-based Chemotherapy w/ or w/o Prior Immunotherapy

Brief description of study

The purpose of the study is to evaluate the efficacy and safety of DS-1062a in subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with actionable genomic alterations and who have been previously been treated with 1 or more kinase inhibitors and platinum-based chemotherapy. We want to know how your body tolerates DS-1062a, how effective DS-1062a may be, and how DS-1062a is taken up by your body when administered intravenously (IV). The study drug DS-1062a is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-00329 Identifier: NCT04484142

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.